Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Von E confirmation reheats

This article was originally published in The Tan Sheet

Executive Summary

Senate Finance chair Chuck Grassley (R-Iowa) places a hold on the nomination of Andrew von Eschenbach's nomination for FDA Commissioner Nov. 17. Grassley objects to the acting commissioner's failure to comply with subpoenas the committee issued in May for FDA documents related to Sanofi-Aventis' antibiotic Ketek. "The authority and integrity of Senate and Committee processes are being challenged," says Grassley. A day earlier, during a hearing on drug safety, Senate Health Committee Chairman Michael Enzi (R-Wyo.) urged colleagues to take up a vote on the nominee. "Give Dr. von Eschenbach the chance to effectively run the FDA with full statutory authority," Enzi said. Holds from Sen. David Vitter (R-La.) and Sen. Jim DeMint (R-S.C.) also remain in place. After the hearing, Enzi told reporters he continues working to lift those holds. If action is not taken during the lame duck session, incoming chair Edward Kennedy (D-Mass.), who supports the nomination, appears likely to continue to press for confirmation...

You may also be interested in...



Congressional Oversight “Misunderstood” By Von Eschenbach – Grassley

Continued criticism of FDA Acting Commissioner Andrew von Eschenbach by Senate Finance Committee Chairman Charles Grassley (R-Iowa) suggests that chances of a Senate vote on the nominee as full commissioner during Congress' lame-duck session have not brightened

The Top Five (Non-COVID) Pharma Stories Of 2020

The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.

The Race To Vaccinate The World Against COVID-19

Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.

Topics

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel